Assessing New Therapies and Lifelong Management Strategies for Congenital Adrenal Hyperplasia
Date/time: Tuesday, August 18, 2026 from 1:00 – 2:30 PM ET
Description: This CME symposium equips clinicians to deliver lifelong, patient-centered care for individuals with congenital adrenal hyperplasia (CAH). Faculty will review the mechanisms, efficacy, safety, and tolerability of current and emerging therapeutic options, highlighting advances that may reshape glucocorticoid management. The session will emphasize shared decision-making strategies tailored to developmental stages, including best practices for transitioning pediatric patients to adult care. Participants will also learn to design comprehensive, evidence-based care plans that address the long‑term metabolic, cardiovascular, reproductive, and psychosocial sequelae of chronic glucocorticoid exposure—even after dose normalization—to optimize outcomes across the lifespan.
Learning Objectives:
- Evaluate the mechanisms, efficacy, safety, and tolerability profiles of current and emerging agents for CAH
- Integrate SDM approaches for patient management across the lifespan, including the transition of pediatric patients to adult care
- Develop comprehensive, evidence-based care plans to address the long-term sequalae arising from chronic glucocorticoid exposure in CAH, even after dose normalization
CMEs:
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
SPEAKERS:
Richard J Auchus, MD, PhD, FACE
Courtney Finlayson, MD
Sponsored by the Med Learning Group
This activity is supported by an educational grant from Neurocrine Biosciences, Inc.
Industry Sponsored Symposium: Shifting The T1D Paradigm: Early Detection, Disease Modification, and Beta-Cell Preservation
When: Wednesday, July 15 I 7:00 – 8:00 PM ET
With the advent of disease-modifying therapies to delay progression of type 1 diabetes (T1D), as well as their potential application of these therapies in newly diagnosed T1D, there is an increased emphasis on presymptomatic screening, staging, and monitoring—representing a true paradigm shift in how we address the disease. This proactive approach is paramount in pediatric populations, who are at higher risk for progression after testing positive for islet autoantibodies. This symposium will provide an overview of the practical considerations for early detection of T1D and the application of disease-modifying therapy for delaying disease progression in pediatric patients, while also exploring emerging treatment approaches aimed at preserving beta cell function in newly diagnosed T1D.
Learning objectives:
- Implement risk-based screening approaches to facilitate timely identification of presymptomatic T1D
- Analyze T1D screening results to determine disease stage and inform appropriate monitoring and referral decisions
- Develop individualized treatment strategies that incorporate disease-modifying therapies to delay T1D progression in eligible patients
- Recognize the importance of beta-cell preservation on T1D prognosis and outcomes
- Review emerging approaches aimed at beta cell preservation & their potential future application in new-onset T1D
CME:1.0 CME/CNE credit available
Speakers:
Daniel DeSalvo, MD
Roshanak Monzavi, MD
This activity is provided by Med Learning Group.
This activity is supported by an educational grant from Sanofi US.
Industry Sponsored Symposium:
Real-World Patient and Clinical Perspectives: Preparing Your Pediatric Patients for Successful Care Transitions in Classic Congenital Adrenal Hyperplasia
Wednesday, March 11, 2026 at 3:00 – 4:00pm ET
Sponsored by Neurocrine BioSciences
Description:
Featuring insights from a patient, caregiver, and an expert healthcare provider and researcher, this presentation highlights the clinical and practical challenges involved in the lifelong management of classic congenital adrenal hyperplasia. The speakers will share valuable takeaways from their own experiences navigating the transition from pediatric to adult endocrinology care.
Attendees will learn about the risks associated with transitions of care, including adrenal crisis and gaps in disease management, and discover strategies for early planning, patient empowerment, and standardized hand-off protocols.
Speakers:
Leslie Pitts, DNP-PhD(c), CPNP-AC, AP-PEN
University of Alabama at Birmingham
School of Nursing
Kevin
A 26-year-old living with classic congenital adrenal hyperplasia and patient ambassador
Trish
Kevin's mother and caregiver ambassador
Sponsored by: Neurocrine BioSciences
Industry Sponsored Symposium:
Exploring Innovative Pathways for Congenital Hyperinsulinism Treatment Pioneering Pathways to Better Health
Wednesday, February 11, 2026 at 10:30 am – 11:30 am ET
Description:
Congenital hyperinsulinemia (CHI) is a complex and serious disorder that most often appears in newborns and young infants as prolonged, often severe, hypoglycemia. When diagnosis or treatment is delayed or inadequate, infants face a real risk of irreversible neurological damage, therefore, timely recognition and prompt intervention are essential.
Current medical and surgical options are limited, leaving many families with few effective choices. New therapies on the horizon may change that landscape — offering options for easier administration, less frequent dosing, improved tolerability, and with a promise of reduced frequency and duration of hypoglycemia.
Join our live webinar where leading experts will confront the critical gaps in CHI care, review real patient cases and outcomes, and evaluate both established treatments and emerging therapies. You’ll gain practical, evidence-based insights to improve early detection, optimize management, and better support families affected by this challenging disease.
Moderator:
Julie Raskin, Chief Executive Officer, Congenital Hyperinsulinism International, Glen Ridge, New Jersey
Speakers:
Diva D. De Leon Crutchlow, MD, MSCE, Division Chief: Endocrinology and Diabetes Children’s Hospital of Philadelphia Professor of Pediatrics University of Pennsylvania Philadelphia, Pennsylvania
Paul S. Thornton, MD, Division Chief, Endocrinology and Diabetes, Cook Children’s Medical Center, Fort Worth, Texas
Sponsored by: Supported by an independent educational grant from Zealand Pharma A/S.
View recording here:
Industry Sponsored Symposium: Advancement in the Delivery of Hydrocortisone
Tuesday, November 11, 2025 at 6:30 PM CT
Description: A discussion that focuses on the necessity of accurate dosing in children with adrenal insufficiency.
Learning objectives:
Review pediatric adrenal insufficiency (AI), including its management, treatment approaches, and monitoring recommendations
Gain an understanding on the history of treatment and explore the role of Alkindi Sprinkle® and Khindivi™, with practical insights on their use in managing pediatric AI.
Speaker:
Courtney A. Finlayson, MD
View the Recording
Password: Webinar_Nov11-25
Sponsored by: eTon Pharmaceuticals
Industry Sponsored Symposium: Increlex (mecasermin) For the Treatment of Severe Primary IGF-1 Deficiency (SPIGFD)
Wednesday, November 5, 2025 at 6:30 CT
Description: An overview of severe primary IGF-1 deficiency and its treatment option.
Learning Objectives:
Review the role of growth hormone and IGF-1 in growth and understand the pathophysiology and differential diagnosis of primary and severe primary IGF-1 deficiency (SPIGFD).
Explore the clinical profile of Increlex® for SPIGFD, including its indication, mechanism of action, efficacy, safety, and practical guidance on dosing and administration.
Speaker:
Dr. Phillipe Backeljauw
Professor of Clinical Pediatrics
University of Cincinnati College of Medicine
Cincinnati Children’s Hospital Medical Center
Division of Pediatric Endocrinology
Industry Sponsored Symposium: Navigating CAH: An Interactive Case Study Approach for Pediatric Specialists
September 10, 2025 I 12:00 – 1:00 PM ET
Sponsored by: Medscape Education. Supported by an independent educational grant from Neurocrine Biosciences, Inc.
PROGRAM DESCRIPTION
Congenital adrenal hyperplasia (CAH) presents complex, lifelong challenges that impact patients' quality of life—from growth suppression in children to long-term metabolic and psychological effects. This symposium offers clinicians a unique opportunity to build confidence in managing CAH, especially amid the emergence of innovative therapies that may reduce reliance on glucocorticoids. Gain insights into timely diagnosis, individualized treatment strategies, and optimizing care during critical transitions such as puberty and adulthood.
Join us to explore cutting-edge advances and improve outcomes for pediatric and adolescent patients living with this rare, often misunderstood condition. Empower your practice with the latest in CAH management.
Learning objectives:
Upon completion of this activity, participants will have greater competence related to:
- Use of new therapeutic approaches for managing pediatric/adolescent patients with CAH
- Comprehensive care in pediatric/adolescent patients with CAH
- Timely diagnosis and management (including intensification or adjustment to pharmacologic management) in pediatric/adolescent patients with CAH
Demonstrate greater confidence in their ability to:
- Comprehensively manage CAH in the pediatric population
CMEs will be offered.
SPEAKERS:
- Richard J. Auchus, MD, PhD, FACE
The James A. Shayman and Andrea
S. Kevrick Professor of Translational Medicine, Division of Metabolism, Endocrinology and Diabetes
Departments of Internal Medicine and Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan - Patricia Y. Fechner, MD
Professor of Pediatrics
University of Washington School of Medicine, Medical Director
Seattle Children's CAH Center of Excellence, Seattle, Washington - Phyllis W. Speiser, MD
Emeritus Professor of Pediatrics
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Sponsored by Medscape Education. Supported by an independent educational grant from Neurocrine Biosciences, Inc.
Wednesday, July 30, 2025 at 6PM EDT
Sponsored by: BioMarin Pharmaceutical, Inc.
PROGRAM DESCRIPTION
This 1-hour Webinar is comprised of eight (8) modules, each focusing on aspects of living with achondroplasia and offering practical recommendations for treatment from the recent 2025 international guidelines.
Learning objectives:
- To provide an overview of the 2025 international consensus guidelines for vosorotide in achondroplasia
- To discuss how the guidelines provide important recommendations for vosoritide use in individuals with achondroplasia, from treatment decision-making, through initiation, follow-up and long-term monitoring
- To illuminate how the guidelines help guide clinicians, individuals, and caregivers throughout the treatment journey
SPEAKERS:
- Philippe F. Backeljauw, MD
Cincinnati Children’s Hospital Medical Center
University of Cincinnati College of MedicineModerator:
Dorna Chu, PharmD
BioMarin Pharmaceutical, Inc.
Sponsored by: BioMarin Pharmaceutical, Inc.
Industry Sponsored Symposium: Reaching Beyond Rickets: Recognizing Hypophosphatasia (HPP) in Your Pediatric Patients
Wednesday, June 25, 2025 | 7:00–8:00 pm ET
Sponsored by Alexion
PROGRAM DESCRIPTION
Join us for interactive case presentations with questions and answers!
Welcome and Introduction
Andrew Dauber, MD, MMSc, Co-Moderator
Chief of Endocrinology
Children’s National Hospital
Washington, District of Columbia
Overview of Hypophosphatasia
Hypophosphatasia in Pediatric Endocrine Practice
Jill Simmons, MD, Co-Moderator
Professor of Pediatrics Ian Burr Division of Pediatric Endocrinology and Diabetes
Director, Program for Pediatric Metabolic Bone Disorders
Vanderbilt University School of Medicine
Nashville, Tennessee
Learning objectives:
- Have increased awareness of hypophosphatasia (HPP), especially in pediatric endocrinology
- Be able to recognize common HPP symptoms and diagnose HPP
Sponsored by: Alexion
Industry Sponsored Symposium: From Referral to Resolution: Untangling the Diagnosis and Treatment of Lipodystrophy
Wednesday, January 29th, 2025 | 6:00–6:20 pm ET
Sponsored by Chiesi
PROGRAM DESCRIPTION
The educational webinar will be a brief case presentation by Dr. Nivedita Patni of a pediatric patient with Acquired Generalized Lipodystrophy. Dr. Patni will discuss the patient presentation, diagnosis, and management strategies she utilized as well as best practices in lipodystrophy. The 20-minute webinar will have the following objectives:
Learning objectives:
- To identify the hallmark clinical signs and symptoms associated with lipodystrophy syndromes
- To discuss the utilization of various tools to help establish a diagnosis for lipodystrophy
- To gain a practical understanding of the management of patients with lipodystrophy and key considerations for treatment
Speaker:
CARLOS FERREIRA, MD
Nivedita Patni M.D. Associate Professor of Pediatrics Division of Pediatric Endocrinology UT Southwestern Medical Center
- Password: PAN2025
Industry Sponsored Symposium: Diagnostic Journey of a Patient with Suspected Skeletal Dysplasia
Wednesday, November 13th, 2024 | 6:00–7:00 pm ET
Sponsored by BioMarin
PROGRAM DESCRIPTION
Learn about the multifaceted diagnostic journey of a patient with suspected skeletal dysplasia.
45-minute presentation | 15-minute audience Q&A
We hope you will join us for a conversation featuring:
Speaker:
CARLOS FERREIRA, MD
Staff Clinician
Metabolic Medicine Branch
Skeletal Genomics Unit
National Human Genome Research Institute (NHGRI)
Bethesda, MD
Moderator:
ANDREW DAUBER, MD, MMSc
Chief of Endocrinology
Children’s National Hospital
Washington, DC
AAP FLEXPEDS (Female Leadership and Excellence in Pediatric Subspecialities) presents: Supporting the Careers of Women Pediatric Physician Scientists – What the NIH has to offer!
November 6th at 4-5:30 pm ET – Women and allies are welcome to attend!
Learning Objectives:
By the end of the webinar, participants will be able to:
1. Understand how trainee and early career women can use the National Institutes of Health (NIH) programs to successfully start and support a career as a woman physician scientist in pediatric
2. Identify programs for funding of research grants and funding supplements to support a career as a woman scientist and caregiver
3. Identify programs to help financially support the reentry of a physician scientist following a leave
Panelists:
- Dr. Karen Winer is the acting chief of Pediatric Growth & Nutrition Branch in the NICHD. For many years, she has served as the program director for the Pediatric Scientist Development Program and the Child Health Research Career Development Award Program, which are national physician-scientist K12 mentoring programs. Dr. Winer completed subspecialty training in pediatric endocrinology at the NIH.
- Catherine Gordon, MD, MS, is clinical director and a senior investigator at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. In her new role, she leads NICHD’s intramural clinical research program to improve understanding of the biological, medical, reproductive, and behavioral aspects of typical and atypical human development. She is also the secretary/treasurer at the APS. She is subspecialized in both adolescent medicine and pediatric endocrinology with research experience in adolescent bone health.
- Erica K. Rosemond is the acting deputy director of NCATS' Division of Clinical Innovation (DCI) and chief of the Clinical and Translational Science Awards (CTSA) Program Branch directing the CTSA Program institutions. She holds a Ph.D. in pharmaceutical sciences, with specialization in neurosciences. Prior to joining NCATS, Rosemond managed grant portfolios at the National Cancer Institute and the National Institute of Mental Health, supporting research education, career development and training.
- Vivian Ota Wang, PhD, FACMG, CGC currently serves as the deputy director of the Office of Research on Women’s Health (ORWH). As a genetic counselor, genomicist, and psychologist, she has experiences in research, education, science policy, and ethics. The ORWH has a diverse range of programs, initiatives, and policies to improve the health of all women at all stages of the life course and to support women in biomedical fields at all stages of their careers.
Hosted by
Barral, Romina; Dammann, Christiane; Hsieh, Helen; Singer, Durga
CME
Credit is NOT available for this webinar. Pending consent from the presenters, the webinar will be recorded and posted on the FLEXPEDS website. A recording will also be sent to those who registered.
Industry Sponsored Symposium: Evolving Treatment Paradigms for Growth Hormone Deficiency: Integrating Novel Therapies
Tuesday, July 30, 2024
7:00 PM - 8:00 PM Eastern
Provided by Haymarket Medical Education
Supported by an educational grant from Novo Nordisk Inc.
PROGRAM DESCRIPTION
Join Drs. Craig Alter, Sara A. DiVall, and Bradley Miller for an engaging discussion of optimal strategies for pediatric GHD management, from diagnosis to the formulation of comprehensive, long-term treatment plans. The panel dialogue will be followed by a “hot seat” discussion of pressing topics in real-world clinical practice, including the use of novel LAGH therapies.
LEARNING OBJECTIVES
After participating in this educational activity, clinicians will be better able to:
- Utilize presentation, genetic, and laboratory findings to make a definitive diagnosis of growth hormone deficiency (GHD)
- Evaluate the efficacy and safety of novel long-acting growth hormone therapies and the place of these agents in evolving GHD treatment paradigms
- Implement strategies to improve treatment adherence and transitions of care for pediatric patients with GHD
AGENDA - 7:00 – 7:30 PM -Part 1: Expert Perspectives
Topics to be discussed by the expert faculty panel include:
- Identifying GHD and Making an Early, Definitive Diagnosis (10 minutes)
- Exploring Long-acting Growth Hormone (LAGH) Formulations (10 minutes)
- Facilitating Treatment Adherence and Transition to Adult Care (10 minutes)
7:30 – 8:00 PM - Part 2: Experts In the Hot Seat
The program Chair will elicit responses from the panel surrounding pressing topics in pediatric GHD care, including:
- Overcoming diagnostic challenges
- Addressing inherent barriers when making a diagnosis of GHD; key nuances of available testing modalities
- The ins and outs of LAGH
- Potential differences in dose initiation of various therapies; adjusting therapy and monitoring efficacy
- Fostering patient/caregiver adherence
- Practical strategies for improving adherence, tips for pivoting from pediatric to adult care
- Q&A
FACULTY
Craig Alter, MD
Director Neuroendocrinology
Professor of Clinical Pediatrics
Children’s Hospital of Philadelphia
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Sara A. DiVall, MD
Associate Professor, Department of Pediatrics
University of Washington
Program Director, Pediatric Endocrinology Fellowship
Seattle Children’s Hospital
Seattle, Washington
Bradley S. Miller, MD, PhD
Director, Division of Endocrinology
Professor, Department of Pediatrics
University of Minnesota Medical School
M Health Fairview Children’s Hospital
Minneapolis, Minnesota
The Clinical Approach to the Child with Lipodystrophy: The Importance of Timely Diagnosis and Intervention
October 30, 2023 from 7:00 – 8:00pm EST
Description:The expert panel will present data detailing the diagnosis and management of pediatric lipodystrophy patients.Moderator:Dr. Ambika AshrafFaculty:Dr. Giovani Ceccarini, Dr. Nivedita Patni, Dr. Rebecca Brown Learning Objectives:
- Understand the role of adipose tissue and leptin in normal physiology.
- Discuss the clinical presentation of lipodystrophy in pediatrics.
- Understand the importance of timely diagnosis and treatment in the pediatric population.
Sponsored by Amryt Pharma
Click here to view the webinar
Early Identification and Effective Management of Hypercholesterolemia in Children
September 28 from 7:00 – 8:00pm EST
This interactive virtual symposium, sponsored by Regeneron Medical Affairs, with Don P. Wilson, MD, a renowned pediatric lipidologist, will focus on diagnosing lipid disorders (including familial hypercholesterolemia) and managing treatment goals in children.
Sponsored by Regeneron Pharmaceuticals, Inc.
Click here to view the webinar
Achondroplasia a Multidisciplinary Conversation on Comprehensive Care
September 14 from 6:00 – 7:00pm EST
Achondroplasia (Ach), the most common skeletal dysplasia with disproportionate short stature, is characterized by a number of medical, functional, and psychosocial challenges across the lifespan of an individual. Up until recently, the treatment of the developmental complications of Ach involved only symptomatic management, surgical intervention, and lifelong follow-up care. An improved understanding of the molecular pathways involved in Ach has resulted in the development of new and emerging targeted therapies for this condition. These novel agents aim to restore bone growth and prevent many of the medical conditions associated with Ach. In this virtual live symposium, an expert panel will address the complications associated with Ach, current care recommendations, strategies for coordination of care with specialists, and new and emerging therapies for Ach.
Herself in Every Moment: A Peer Conversation on the Importance of Individualized Treatment for Children with CPP
This presentation features a patient case and relevant data from two newly published studies and focuses on the need for timely and ongoing treatment.
Click here for more information and the recording
Improving Outcomes in Pediatric Growth Hormone Deficiency With Effective Diagnosis and Personalized Management Strategies
July 13, 2023 7:00-8:00 PM ET
The availability of recombinant human growth hormone (r-hGH) has facilitated wider treatment of growth hormone deficiency. Join this CME-certified PeerView MasterClass & Practicum symposium to increase your knowledge and competence about the diagnosis and management of growth hormone deficiency with r-hGH therapy, including long-acting growth hormone agents.
Expert faculty will review current guidelines for growth hormone deficiency diagnosis, growth hormone therapy indications, and characteristics of available and emerging growth hormone therapies. You will also gain a better understanding of how to address patient and/or caregiver needs and preferences to promote r-hGH adherence.
Industry Sponsored Symposium:
Real-World Patient and Clinical Perspectives: Preparing Your Pediatric Patients for Successful Care Transitions in Classic Congenital Adrenal Hyperplasia
Wednesday, March 11, 2026 at 3:00 – 4:00pm ET
Sponsored by Neurocrine BioSciences
Description:
Featuring insights from a patient, caregiver, and an expert healthcare provider and researcher, this presentation highlights the clinical and practical challenges involved in the lifelong management of classic congenital adrenal hyperplasia. The speakers will share valuable takeaways from their own experiences navigating the transition from pediatric to adult endocrinology care.
Attendees will learn about the risks associated with transitions of care, including adrenal crisis and gaps in disease management, and discover strategies for early planning, patient empowerment, and standardized hand-off protocols.
Speakers:
Leslie Pitts, DNP-PhD(c), CPNP-AC, AP-PEN
University of Alabama at Birmingham
School of Nursing
Kevin
A 26-year-old living with classic congenital adrenal hyperplasia and patient ambassador
Trish
Kevin's mother and caregiver ambassador
Sponsored by: Neurocrine BioSciences
Industry Sponsored Symposium:
Exploring Innovative Pathways for Congenital Hyperinsulinism Treatment Pioneering Pathways to Better Health
Wednesday, February 11, 2026 at 10:30 am – 11:30 am ET
Description:
Congenital hyperinsulinemia (CHI) is a complex and serious disorder that most often appears in newborns and young infants as prolonged, often severe, hypoglycemia. When diagnosis or treatment is delayed or inadequate, infants face a real risk of irreversible neurological damage, therefore, timely recognition and prompt intervention are essential.
Current medical and surgical options are limited, leaving many families with few effective choices. New therapies on the horizon may change that landscape — offering options for easier administration, less frequent dosing, improved tolerability, and with a promise of reduced frequency and duration of hypoglycemia.
Join our live webinar where leading experts will confront the critical gaps in CHI care, review real patient cases and outcomes, and evaluate both established treatments and emerging therapies. You’ll gain practical, evidence-based insights to improve early detection, optimize management, and better support families affected by this challenging disease.
Moderator:
Julie Raskin, Chief Executive Officer, Congenital Hyperinsulinism International, Glen Ridge, New Jersey
Speakers:
Diva D. De Leon Crutchlow, MD, MSCE, Division Chief: Endocrinology and Diabetes Children’s Hospital of Philadelphia Professor of Pediatrics University of Pennsylvania Philadelphia, Pennsylvania
Paul S. Thornton, MD, Division Chief, Endocrinology and Diabetes, Cook Children’s Medical Center, Fort Worth, Texas
Sponsored by: Supported by an independent educational grant from Zealand Pharma A/S.
View recording here:
Industry Sponsored Symposium: Advancement in the Delivery of Hydrocortisone
Tuesday, November 11 at 6:30 PM CT
Description: A discussion that focuses on the necessity of accurate dosing in children with adrenal insufficiency.
Learning objectives:
Review pediatric adrenal insufficiency (AI), including its management, treatment approaches, and monitoring recommendations
Gain an understanding on the history of treatment and explore the role of Alkindi Sprinkle® and Khindivi™, with practical insights on their use in managing pediatric AI.
Speaker:
Courtney A. Finlayson, MD
View the Recording
Password: Webinar_Nov11-25
Sponsored by: eTon Pharmaceuticals
Industry Sponsored Symposium: Increlex (mecasermin) For the Treatment of Severe Primary IGF-1 Deficiency (SPIGFD)
Wednesday, November 5, at 6:30 CT
Description: An overview of severe primary IGF-1 deficiency and its treatment option.
Learning Objectives:
Review the role of growth hormone and IGF-1 in growth and understand the pathophysiology and differential diagnosis of primary and severe primary IGF-1 deficiency (SPIGFD).
Explore the clinical profile of Increlex® for SPIGFD, including its indication, mechanism of action, efficacy, safety, and practical guidance on dosing and administration.
Speaker:
Dr. Phillipe Backeljauw
Professor of Clinical Pediatrics
University of Cincinnati College of Medicine
Cincinnati Children’s Hospital Medical Center
Division of Pediatric Endocrinology
Industry Sponsored Symposium: Navigating CAH: An Interactive Case Study Approach for Pediatric Specialists
September 10, 2025 I 12:00 – 1:00 PM ET
Sponsored by: Medscape Education. Supported by an independent educational grant from Neurocrine Biosciences, Inc.
PROGRAM DESCRIPTION
Congenital adrenal hyperplasia (CAH) presents complex, lifelong challenges that impact patients' quality of life—from growth suppression in children to long-term metabolic and psychological effects. This symposium offers clinicians a unique opportunity to build confidence in managing CAH, especially amid the emergence of innovative therapies that may reduce reliance on glucocorticoids. Gain insights into timely diagnosis, individualized treatment strategies, and optimizing care during critical transitions such as puberty and adulthood.
Join us to explore cutting-edge advances and improve outcomes for pediatric and adolescent patients living with this rare, often misunderstood condition. Empower your practice with the latest in CAH management.
Learning objectives:
Upon completion of this activity, participants will have greater competence related to:
- Use of new therapeutic approaches for managing pediatric/adolescent patients with CAH
- Comprehensive care in pediatric/adolescent patients with CAH
- Timely diagnosis and management (including intensification or adjustment to pharmacologic management) in pediatric/adolescent patients with CAH
Demonstrate greater confidence in their ability to:
- Comprehensively manage CAH in the pediatric population
CMEs will be offered.
SPEAKERS:
- Richard J. Auchus, MD, PhD, FACE
The James A. Shayman and Andrea
S. Kevrick Professor of Translational Medicine, Division of Metabolism, Endocrinology and Diabetes
Departments of Internal Medicine and Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan - Patricia Y. Fechner, MD
Professor of Pediatrics
University of Washington School of Medicine, Medical Director
Seattle Children's CAH Center of Excellence, Seattle, Washington - Phyllis W. Speiser, MD
Emeritus Professor of Pediatrics
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Sponsored by Medscape Education. Supported by an independent educational grant from Neurocrine Biosciences, Inc.
Wednesday, July 30, 2025 at 6PM EDT
Sponsored by: BioMarin Pharmaceutical, Inc.
PROGRAM DESCRIPTION
This 1-hour Webinar is comprised of eight (8) modules, each focusing on aspects of living with achondroplasia and offering practical recommendations for treatment from the recent 2025 international guidelines.
Learning objectives:
- To provide an overview of the 2025 international consensus guidelines for vosorotide in achondroplasia
- To discuss how the guidelines provide important recommendations for vosoritide use in individuals with achondroplasia, from treatment decision-making, through initiation, follow-up and long-term monitoring
- To illuminate how the guidelines help guide clinicians, individuals, and caregivers throughout the treatment journey
SPEAKERS:
- Philippe F. Backeljauw, MD
Cincinnati Children’s Hospital Medical Center
University of Cincinnati College of MedicineModerator:
Dorna Chu, PharmD
BioMarin Pharmaceutical, Inc.
Sponsored by: BioMarin Pharmaceutical, Inc.
Industry Sponsored Symposium: Reaching Beyond Rickets: Recognizing Hypophosphatasia (HPP) in Your Pediatric Patients
Wednesday, June 25, 2025 | 7:00–8:00 pm ET
Sponsored by Alexion
PROGRAM DESCRIPTION
Join us for interactive case presentations with questions and answers!
Welcome and Introduction
Andrew Dauber, MD, MMSc, Co-Moderator
Chief of Endocrinology
Children’s National Hospital
Washington, District of Columbia
Overview of Hypophosphatasia
Hypophosphatasia in Pediatric Endocrine Practice
Jill Simmons, MD, Co-Moderator
Professor of Pediatrics Ian Burr Division of Pediatric Endocrinology and Diabetes
Director, Program for Pediatric Metabolic Bone Disorders
Vanderbilt University School of Medicine
Nashville, Tennessee
Learning objectives:
- Have increased awareness of hypophosphatasia (HPP), especially in pediatric endocrinology
- Be able to recognize common HPP symptoms and diagnose HPP
Sponsored by: Alexion
Industry Sponsored Symposium: From Referral to Resolution: Untangling the Diagnosis and Treatment of Lipodystrophy
Wednesday, January 29th, 2025 | 6:00–6:20 pm ET
Sponsored by Chiesi
PROGRAM DESCRIPTION
The educational webinar will be a brief case presentation by Dr. Nivedita Patni of a pediatric patient with Acquired Generalized Lipodystrophy. Dr. Patni will discuss the patient presentation, diagnosis, and management strategies she utilized as well as best practices in lipodystrophy. The 20-minute webinar will have the following objectives:
Learning objectives:
- To identify the hallmark clinical signs and symptoms associated with lipodystrophy syndromes
- To discuss the utilization of various tools to help establish a diagnosis for lipodystrophy
- To gain a practical understanding of the management of patients with lipodystrophy and key considerations for treatment
Speaker:
CARLOS FERREIRA, MD
Nivedita Patni M.D. Associate Professor of Pediatrics Division of Pediatric Endocrinology UT Southwestern Medical Center
- Password: PAN2025
Industry Sponsored Symposium: Diagnostic Journey of a Patient with Suspected Skeletal Dysplasia
Wednesday, November 13th, 2024 | 6:00–7:00 pm ET
Sponsored by BioMarin
PROGRAM DESCRIPTION
Learn about the multifaceted diagnostic journey of a patient with suspected skeletal dysplasia.
45-minute presentation | 15-minute audience Q&A
We hope you will join us for a conversation featuring:
Speaker:
CARLOS FERREIRA, MD
Staff Clinician
Metabolic Medicine Branch
Skeletal Genomics Unit
National Human Genome Research Institute (NHGRI)
Bethesda, MD
Moderator:
ANDREW DAUBER, MD, MMSc
Chief of Endocrinology
Children’s National Hospital
Washington, DC
AAP FLEXPEDS (Female Leadership and Excellence in Pediatric Subspecialities) presents: Supporting the Careers of Women Pediatric Physician Scientists – What the NIH has to offer!
November 6th at 4-5:30 pm ET – Women and allies are welcome to attend!
Learning Objectives:
By the end of the webinar, participants will be able to:
1. Understand how trainee and early career women can use the National Institutes of Health (NIH) programs to successfully start and support a career as a woman physician scientist in pediatric
2. Identify programs for funding of research grants and funding supplements to support a career as a woman scientist and caregiver
3. Identify programs to help financially support the reentry of a physician scientist following a leave
Panelists:
- Dr. Karen Winer is the acting chief of Pediatric Growth & Nutrition Branch in the NICHD. For many years, she has served as the program director for the Pediatric Scientist Development Program and the Child Health Research Career Development Award Program, which are national physician-scientist K12 mentoring programs. Dr. Winer completed subspecialty training in pediatric endocrinology at the NIH.
- Catherine Gordon, MD, MS, is clinical director and a senior investigator at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. In her new role, she leads NICHD’s intramural clinical research program to improve understanding of the biological, medical, reproductive, and behavioral aspects of typical and atypical human development. She is also the secretary/treasurer at the APS. She is subspecialized in both adolescent medicine and pediatric endocrinology with research experience in adolescent bone health.
- Erica K. Rosemond is the acting deputy director of NCATS' Division of Clinical Innovation (DCI) and chief of the Clinical and Translational Science Awards (CTSA) Program Branch directing the CTSA Program institutions. She holds a Ph.D. in pharmaceutical sciences, with specialization in neurosciences. Prior to joining NCATS, Rosemond managed grant portfolios at the National Cancer Institute and the National Institute of Mental Health, supporting research education, career development and training.
- Vivian Ota Wang, PhD, FACMG, CGC currently serves as the deputy director of the Office of Research on Women’s Health (ORWH). As a genetic counselor, genomicist, and psychologist, she has experiences in research, education, science policy, and ethics. The ORWH has a diverse range of programs, initiatives, and policies to improve the health of all women at all stages of the life course and to support women in biomedical fields at all stages of their careers.
Hosted by
Barral, Romina; Dammann, Christiane; Hsieh, Helen; Singer, Durga
CME
Credit is NOT available for this webinar. Pending consent from the presenters, the webinar will be recorded and posted on the FLEXPEDS website. A recording will also be sent to those who registered.
Industry Sponsored Symposium: Evolving Treatment Paradigms for Growth Hormone Deficiency: Integrating Novel Therapies
Tuesday, July 30, 2024
7:00 PM - 8:00 PM Eastern
Provided by Haymarket Medical Education
Supported by an educational grant from Novo Nordisk Inc.
PROGRAM DESCRIPTION
Join Drs. Craig Alter, Sara A. DiVall, and Bradley Miller for an engaging discussion of optimal strategies for pediatric GHD management, from diagnosis to the formulation of comprehensive, long-term treatment plans. The panel dialogue will be followed by a “hot seat” discussion of pressing topics in real-world clinical practice, including the use of novel LAGH therapies.
LEARNING OBJECTIVES
After participating in this educational activity, clinicians will be better able to:
- Utilize presentation, genetic, and laboratory findings to make a definitive diagnosis of growth hormone deficiency (GHD)
- Evaluate the efficacy and safety of novel long-acting growth hormone therapies and the place of these agents in evolving GHD treatment paradigms
- Implement strategies to improve treatment adherence and transitions of care for pediatric patients with GHD
AGENDA - 7:00 – 7:30 PM -Part 1: Expert Perspectives
Topics to be discussed by the expert faculty panel include:
- Identifying GHD and Making an Early, Definitive Diagnosis (10 minutes)
- Exploring Long-acting Growth Hormone (LAGH) Formulations (10 minutes)
- Facilitating Treatment Adherence and Transition to Adult Care (10 minutes)
7:30 – 8:00 PM - Part 2: Experts In the Hot Seat
The program Chair will elicit responses from the panel surrounding pressing topics in pediatric GHD care, including:
- Overcoming diagnostic challenges
- Addressing inherent barriers when making a diagnosis of GHD; key nuances of available testing modalities
- The ins and outs of LAGH
- Potential differences in dose initiation of various therapies; adjusting therapy and monitoring efficacy
- Fostering patient/caregiver adherence
- Practical strategies for improving adherence, tips for pivoting from pediatric to adult care
- Q&A
FACULTY
Craig Alter, MD
Director Neuroendocrinology
Professor of Clinical Pediatrics
Children’s Hospital of Philadelphia
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Sara A. DiVall, MD
Associate Professor, Department of Pediatrics
University of Washington
Program Director, Pediatric Endocrinology Fellowship
Seattle Children’s Hospital
Seattle, Washington
Bradley S. Miller, MD, PhD
Director, Division of Endocrinology
Professor, Department of Pediatrics
University of Minnesota Medical School
M Health Fairview Children’s Hospital
Minneapolis, Minnesota
The Clinical Approach to the Child with Lipodystrophy: The Importance of Timely Diagnosis and Intervention
October 30, 2023 from 7:00 – 8:00pm EST
Description:The expert panel will present data detailing the diagnosis and management of pediatric lipodystrophy patients.Moderator:Dr. Ambika AshrafFaculty:Dr. Giovani Ceccarini, Dr. Nivedita Patni, Dr. Rebecca Brown Learning Objectives:
- Understand the role of adipose tissue and leptin in normal physiology.
- Discuss the clinical presentation of lipodystrophy in pediatrics.
- Understand the importance of timely diagnosis and treatment in the pediatric population.
Sponsored by Amryt Pharma
Click here to view the webinar
Early Identification and Effective Management of Hypercholesterolemia in Children
September 28 from 7:00 – 8:00pm EST
This interactive virtual symposium, sponsored by Regeneron Medical Affairs, with Don P. Wilson, MD, a renowned pediatric lipidologist, will focus on diagnosing lipid disorders (including familial hypercholesterolemia) and managing treatment goals in children.
Sponsored by Regeneron Pharmaceuticals, Inc.
Click here to view the webinar
Achondroplasia a Multidisciplinary Conversation on Comprehensive Care
September 14 from 6:00 – 7:00pm EST
Achondroplasia (Ach), the most common skeletal dysplasia with disproportionate short stature, is characterized by a number of medical, functional, and psychosocial challenges across the lifespan of an individual. Up until recently, the treatment of the developmental complications of Ach involved only symptomatic management, surgical intervention, and lifelong follow-up care. An improved understanding of the molecular pathways involved in Ach has resulted in the development of new and emerging targeted therapies for this condition. These novel agents aim to restore bone growth and prevent many of the medical conditions associated with Ach. In this virtual live symposium, an expert panel will address the complications associated with Ach, current care recommendations, strategies for coordination of care with specialists, and new and emerging therapies for Ach.
Herself in Every Moment: A Peer Conversation on the Importance of Individualized Treatment for Children with CPP
This presentation features a patient case and relevant data from two newly published studies and focuses on the need for timely and ongoing treatment.
Click here for more information and the recording
Improving Outcomes in Pediatric Growth Hormone Deficiency With Effective Diagnosis and Personalized Management Strategies
July 13, 2023 7:00-8:00 PM ET
The availability of recombinant human growth hormone (r-hGH) has facilitated wider treatment of growth hormone deficiency. Join this CME-certified PeerView MasterClass & Practicum symposium to increase your knowledge and competence about the diagnosis and management of growth hormone deficiency with r-hGH therapy, including long-acting growth hormone agents.
Expert faculty will review current guidelines for growth hormone deficiency diagnosis, growth hormone therapy indications, and characteristics of available and emerging growth hormone therapies. You will also gain a better understanding of how to address patient and/or caregiver needs and preferences to promote r-hGH adherence.